Latest ERBB Stories
The main cause of death in women with breast cancer is spread of the original tumor to distant sites, a process known as metastasis.
CAMBRIDGE, Mass., April 20, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.
Implications for blocking metastasis and improving responses to existing therapies.
PRINCETON, N.J., Oct.
CAMBRIDGE, Mass., July 22 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.
MM-111 antibody uses HER2 target to reach and block HER3.
CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Merrimack Pharmaceuticals' MM-111 Team Leader Charlotte McDonagh, Ph.D., will discuss the development of this novel, bispecific antibody on Tuesday, May 4, at the BIO 2010 International Convention in Chicago, Illinois.
CAMBRIDGE, Mass., Feb. 22 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva(Â®) (erlotinib) in patients with non-small cell lung cancer (NSCLC).
- Global Phase 3 Program Expected to Begin in December - COLLEGEVILLE, Pa., Dec.
- A serpent whose bite was fabled to produce intense thirst.